Bolt Biotherapeutics (BOLT)
BOLT · BiotechSign PipelinePipeline Overview
- Therapeutic Focus
- Oncologysrc
Signal Snapshot
1
Clinical Trial (ClinicalTrials.gov aggregate)
0
Catalyst Records
5
Publications on Record
1 Phase 1, 1 Phase 2
Trial Phase Mix
ClinicalTrials.gov aggregate as of 2026-09-28. Source
Recent Publications
- Phase 1/1b open-label, first-in-human study of HER2×CD3×CD28 trispecific T-cell engager (SAR443216) in participants with R/R HER2-expressing solid tumors. — J Immunother Cancer (2026) PMID 42705861
- SKYSCRAPER-01: Tiragolumab in Combination With Atezolizumab in Previously Untreated PD-L1-High, Locally Advanced, Unresectable or Metastatic Non-Small Cell Lung Cancer. — J Clin Oncol (2026) PMID 42507968
5 total publications tracked — view all on BiotechSign
Get real-time catalyst alerts, analyst signals, dilution risk scores, and full pipeline data for Bolt Biotherapeutics.
Full BOLT Data Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.